Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135406 · ClinicalTrials.gov registry record · Phase 1
CART-19 for Multiple Myeloma
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02135406: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT02135406 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02135406, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary goals: determine the safety, tolerability and engraftment potential of CART-19 T cells in patients undergoing salvage ASCT after early relapse following first ASCT. CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR(zeta):41BB administered by intravenous infusion using a single infusion of 1-5x108 CART19-transduced T cells on day +2 after autologous stem cell infusion following high-dose melphalan.
Interventions
- BIOLOGICAL CART-19 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135406
The ClinicalTrials.gov registry entry for NCT02135406 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART-19 T cells is the first listed.
NCT02135406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02135406 about?
NCT02135406 is a clinical study titled "CART-19 for Multiple Myeloma". The primary goals: determine the safety, tolerability and engraftment potential of CART-19 T cells in patients undergoing salvage ASCT after early relapse following first ASCT. CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR(zeta):41BB administered by intravenous infu...
What is the current status of trial NCT02135406?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2014-05. Estimated completion is 2018-01-18.
What interventions are being tested in trial NCT02135406?
The interventions under investigation include: CART-19 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02135406?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.